Heartflow, Inc.(HTFL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,351 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
HTFL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Heartflow, Inc. (HTFL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HTFL at 34.3/100 on a 32-signal composite quality model, placing it at rank #2,351 of 2,962 stocks — the bottom half of the AI-ranked universe. HTFL scores in the top quartile across institutional flow (99.6), revenue growth (81.0). Areas of concern include balance sheet strength (3.9) and profitability (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Heartflow, Inc. reports quarterly revenue of $64.1M, net income of $-15.7M, free cash flow of $-10.5M. Top institutional holders of HTFL by reported 13-F value include XXEC, Bain Capital Life Sciences Investors, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. HTFL trades on the Nasdaq exchange and files with the SEC under CIK 1464521. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HTFL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Heartflow, Inc. directly from SEC EDGAR. Heartflow, Inc.'s 13F Pro composite quality score has ranged between 29 and 38 since 2026, currently 34.3 — a stable long-term trajectory across 28 quarterly and live scoring snapshots.
Revenue
Q2 2026
$64.1M
Net Income
Q2 2026
$-15.7M
Free Cash Flow
Q2 2026
$-10.5M
ROIC
Q2 2026
-25.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+39.9% YoYNet Income
-21.1% YoYOperating Income
-4.6% YoYEPS (Diluted)
-129.2% YoYTotal Assets
+202.8% YoYOp. Cash Flow
+21.7% YoYFree Cash Flow
+19.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $176.0M +39.9% | $125.8M +44.3% | $87.2M | — |
| Net Income | $-116.8M -21.1% | $-96.4M -0.8% | $-95.7M | — |
| Operating Income | $-64.1M -4.6% | $-61.2M +16.0% | $-72.9M | — |
| EPS (Diluted) | $-3.17 -129.2% | $-1.38 +29.0% | $-1.95 | — |
| Total Assets | $359.5M +202.8% | $118.7M | — | — |
| Operating Cash Flow | $-54.0M +21.7% | $-69.0M +9.7% | $-76.4M | — |
| Free Cash Flow | $-59.0M +19.5% | $-73.4M +11.1% | $-82.5M | — |
Get alerted when HTFL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Heartflow, Inc. including:
Top Institutional Holders of HTFL
XXEC, Inc.
$2.5B77,270,845 shBain Capital Life Sciences Investors, LLC
$247.9M8,448,158 shWELLINGTON MANAGEMENT GROUP LLP
$230.7M7,864,226 shBlackRock, Inc.
$152.5M5,197,747 shFMR LLC
$141.4M4,820,944 shVANGUARD PORTFOLIO MANAGEMENT LLC
$105.2M3,584,428 shBAMCO INC /NY/
$94.6M3,225,133 shVANGUARD CAPITAL MANAGEMENT LLC
$80.8M2,753,206 shJupiter Topco LLC
$71.0M2,419,336 shInvesco Ltd.
$67.4M2,298,718 sh
| Fund | Value | Shares |
|---|---|---|
| XXEC, Inc. | $2.5B | 77,270,845 |
| Bain Capital Life Sciences Investors, LLC | $247.9M | 8,448,158 |
| WELLINGTON MANAGEMENT GROUP LLP | $230.7M | 7,864,226 |
| BlackRock, Inc. | $152.5M | 5,197,747 |
| FMR LLC | $141.4M | 4,820,944 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $105.2M | 3,584,428 |
| BAMCO INC /NY/ | $94.6M | 3,225,133 |
| VANGUARD CAPITAL MANAGEMENT LLC | $80.8M | 2,753,206 |
| Jupiter Topco LLC | $71.0M | 2,419,336 |
| Invesco Ltd. | $67.4M | 2,298,718 |
Companies Similar to HTFL
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Axsome Therapeutics, Inc.
Axogen, Inc.
Xilio Therapeutics, Inc.
4D Molecular Therapeutics, Inc.
GLAUKOS Corp
Butterfly Network, Inc.
INSMED Inc
Ultragenyx Pharmaceutical Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put HTFL on your watchlist
Track score changes the day Heartflow, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HTFL a good stock to buy?
13F Pro's AI-powered analysis of Heartflow, Inc. (HTFL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HTFL are available on the HTFL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HTFL is classified as a mid company.
Which hedge funds own HTFL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HTFL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Heartflow, Inc.'s investment landscape.